精确分子工程治疗霍奇金病到基因治疗方法的疗效和细微差别

IF 0.8 4区医学 Q4 IMMUNOLOGY

Critical Reviews in Immunology Pub Date : 2024-02-01 DOI:10.1615/critrevimmunol.2024052378

Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain

{"title":"精确分子工程治疗霍奇金病到基因治疗方法的疗效和细微差别","authors":"Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain","doi":"10.1615/critrevimmunol.2024052378","DOIUrl":null,"url":null,"abstract":"Gene therapy is a particularly useful treatment for nervous system genetic illnesses, including those induced especially by infectious organisms and antigens, and is being utilized to treat Hodgkin's disease. Due to the possible clonal relationship between both disorders, immunotherapy directed against CD20 positive cells may be a more effective treatment in patients with persistent HD and NHL.HL growth can be inhibited both in vitro and in vivo by AdsIL-13Ralpha2. High-dose treatment combined with stem cell transplantation has been effective in treating HIV-negative lymphoma that has progressed to high-risk or relapsed illness. For therapy, LMP2-specific CTL will be used. Furthermore, it is possible to view the cytotoxicity of genetically modified adenoviruses that express proteins such as p27Kip1, p21Waf1, and p16INK4A as a foundational element for (2;5)-derived ALCL genetic treatment for Hodgkin's disease","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":"1 1","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach\",\"authors\":\"Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain\",\"doi\":\"10.1615/critrevimmunol.2024052378\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Gene therapy is a particularly useful treatment for nervous system genetic illnesses, including those induced especially by infectious organisms and antigens, and is being utilized to treat Hodgkin's disease. Due to the possible clonal relationship between both disorders, immunotherapy directed against CD20 positive cells may be a more effective treatment in patients with persistent HD and NHL.HL growth can be inhibited both in vitro and in vivo by AdsIL-13Ralpha2. High-dose treatment combined with stem cell transplantation has been effective in treating HIV-negative lymphoma that has progressed to high-risk or relapsed illness. For therapy, LMP2-specific CTL will be used. Furthermore, it is possible to view the cytotoxicity of genetically modified adenoviruses that express proteins such as p27Kip1, p21Waf1, and p16INK4A as a foundational element for (2;5)-derived ALCL genetic treatment for Hodgkin's disease\",\"PeriodicalId\":55205,\"journal\":{\"name\":\"Critical Reviews in Immunology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical Reviews in Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1615/critrevimmunol.2024052378\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/critrevimmunol.2024052378","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

基因疗法是治疗神经系统遗传疾病（包括由传染性生物体和抗原诱发的疾病）的一种特别有效的方法，目前正被用于治疗霍奇金病。由于这两种疾病之间可能存在克隆关系，针对 CD20 阳性细胞的免疫疗法可能是治疗顽固性 HD 和 NHL 患者的更有效方法。AdsIL-13Ralpha2 可在体外和体内抑制 HL 的生长。大剂量治疗结合干细胞移植对治疗进展为高危或复发的HIV阴性淋巴瘤很有效。在治疗中，将使用 LMP2 特异性 CTL。此外，还可以将表达p27Kip1、p21Waf1和p16INK4A等蛋白的转基因腺病毒的细胞毒性视为（2;5）衍生ALCL基因治疗霍奇金病的基础要素

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach

Gene therapy is a particularly useful treatment for nervous system genetic illnesses, including those induced especially by infectious organisms and antigens, and is being utilized to treat Hodgkin's disease. Due to the possible clonal relationship between both disorders, immunotherapy directed against CD20 positive cells may be a more effective treatment in patients with persistent HD and NHL.HL growth can be inhibited both in vitro and in vivo by AdsIL-13Ralpha2. High-dose treatment combined with stem cell transplantation has been effective in treating HIV-negative lymphoma that has progressed to high-risk or relapsed illness. For therapy, LMP2-specific CTL will be used. Furthermore, it is possible to view the cytotoxicity of genetically modified adenoviruses that express proteins such as p27Kip1, p21Waf1, and p16INK4A as a foundational element for (2;5)-derived ALCL genetic treatment for Hodgkin's disease

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Critical Reviews in Immunology 医学-免疫学

CiteScore

2.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Immunology covers a broad spectrum of investigations at the genes, molecular, cellular, organ and system levels to reveal defense mechanisms against pathogens as well as protection against tumors and autoimmune diseases. The great advances in immunology in recent years make this field one of the most dynamic and rapidly growing in medical sciences. Critical ReviewsTM in Immunology (CRI) seeks to present a balanced overview of contemporary adaptive and innate immune responses related to autoimmunity, tumor, microbe, transplantation, neuroimmunology, immune regulation and immunotherapy from basic to translational aspects in health and disease. The articles that appear in CRI are mostly obtained by invitations to active investigators. But the journal will also consider proposals from the scientific community. Interested investigators should send their inquiries to the editor before submitting a manuscript.